LEXEO Therapeutics is a clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.
Founded in 2018 based on 25 years of research at a leading scientific institution, LEXEO's investigational therapies have the potential to offer gene therapy-based treatments to address many diseases that have eluded today's existing drug delivery platforms.
LEXEO’s mission is to lead the field of gene therapy as a fully integrated biotechnology company; discovering, developing and delivering treatments and cures to some of today's most devastating diseases.